Back to Search
Start Over
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
- Source :
- Transplantation and Cellular Therapy
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Data are scarce regarding both the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing immune cell therapy; thus, we prospectively evaluated these two domains in patients receiving this vaccine after allogeneic hematopoietic cell transplantation (HCT; n = 66) or after CD19-based chimeric antigen receptor T cell (CART) therapy (n = 14). Overall, the vaccine was well tolerated, with mild non-hematologic vaccine-reported adverse events in a minority of the patients. Twelve percent of the patients after the first dose and 10% of the patients after the second dose developed cytopenia, and there were three cases of graft-versus-host disease exacerbation after each dose. A single case of impending graft rejection was summarized as possibly related. Evaluation of immunogenicity showed that 57% of patients after CART infusion and 75% patients after allogeneic HCT had evidence of humoral and/or cellular response to the vaccine. The Cox regression model indicated that longer time from infusion of cells, female sex, and higher CD19+ cells were associated with a positive humoral response, whereas a higher CD4+/CD8+ ratio was correlated with a positive cellular response, as confirmed by the ELISpot test. We conclude that the BNT162b2 mRNA COVID-19 vaccine has impressive immunogenicity in patients after allogeneic HCT or CART. Adverse events were mostly mild and transient, but some significant hematologic events were observed; hence, patients should be closely monitored.
- Subjects :
- Oncology
medicine.medical_specialty
COVID-19 Vaccines
medicine.medical_treatment
Hematopoietic stem cell transplantation
Article
Cell therapy
immune system diseases
Internal medicine
Humans
CART
Immunology and Allergy
Medicine
Prospective Studies
RNA, Messenger
Adverse effect
BNT162 Vaccine
Transplantation
Cytopenia
SARS-CoV-2
business.industry
Immunogenicity
ELISPOT
Hematopoietic Stem Cell Transplantation
COVID-19
Cell Biology
Hematology
vaccination
medicine.disease
Vaccination
HCT
Molecular Medicine
Female
business
Subjects
Details
- ISSN :
- 26666367
- Volume :
- 27
- Database :
- OpenAIRE
- Journal :
- Transplantation and Cellular Therapy
- Accession number :
- edsair.doi.dedup.....b78ec0e8d251a2beb709251294167512